Potential pathophysiological role of endothelin-1 in asthma

Area of Science:

• Pulmonary Medicine
• Endocrinology
• Pharmacology

Background:

• Endothelin-1 (ET-1), initially known for cardiovascular effects, exhibits diverse biological activities, including in the pulmonary system.
• Investigating ET-1's role in asthma requires fulfilling specific criteria for a pathophysiologically relevant mediator.

Purpose of the Study:

• To evaluate the evidence supporting endothelin-1 (ET-1) as a key mediator in asthma pathogenesis.
• To assess whether ET-1 fulfills established criteria for a relevant mediator in lung pathophysiology, particularly in asthma.

Main Methods:

• Review of existing literature on ET-1 synthesis, release, metabolism, and receptor localization in the lung.
• Analysis of ET-1's effects in preclinical asthma models and its correlation with disease severity in asthmatic patients.
• Examination of the therapeutic potential of ET-1 pathway inhibitors in asthma.

Main Results:

• Pathways for ET-1 synthesis, release, and metabolism are present in the lung, with ET receptors found on relevant pulmonary cells.
• ET-1 mimics asthma features, and elevated levels correlate with disease severity in asthmatic patients.
• Preclinical studies suggest efficacy of ET receptor antagonists and ECE inhibitors in asthma models.

Conclusions:

• Endothelin-1 (ET-1) meets several criteria suggesting its involvement in asthma pathogenesis.
• While preclinical data is promising, definitive conclusions on ET-1's role require clinical trial results for selective ET receptor antagonists and ECE inhibitors in asthma.